Clinical guidelines for treating opioid use disorder (OUD) recommend incremental dose titration for methadone and buprenorphine/naloxone to reach a safe therapeutic maintenance dose. Those recommendations rely largely on pharmacologic rationale, expert consensus, and clinical experience rather than large-scale real-world evidence. The protocol highlights a specific gap in evidence where fentanyl is widespread: higher opioid tolerance among people initiating treatment could render traditional titration schedules insufficient. This study aims to generate population-based evidence to inform safe and effective titration strategies.
The protocol defines two primary objectives: to compare alternative titration schedules for methadone and buprenorphine/naloxone with respect to (1) achieving completed induction and (2) time to all-cause mortality. Secondary objectives include evaluation of overdose-related acute care visits or overdose-related death and treatment discontinuation across titration schedules.
This is a retrospective population-based cohort study using linked administrative health data from nine provincial databases in British Columbia, Canada. The investigators will use a target trial emulation framework to estimate per-protocol effects of sustained titration schedules. The protocol specifies use of a clone-censor-weight approach to emulate adherence to assigned titration regimens and to account for deviations from those regimens in routine care.
The study population comprises adults aged 18 years or older in British Columbia who initiated methadone or buprenorphine/naloxone between 01/01/2010 and 30/06/2022. Further cohort definitions, inclusion/exclusion specifics, and covariates to be used for confounding control are described in the full protocol (supplementary materials referenced), and analytic cohorts for sensitivity checks will be defined using cohort and timeline restrictions.
The exposures of interest are alternative titration schedules for methadone and buprenorphine/naloxone. The protocol will operationalize sustained titration schedules and define adherence and deviations from those schedules within administrative dispensing and clinical records. Completed induction is operationalized as no dose increase for at least two weeks without any intervening decrease, which serves as a practical marker of having reached a stable therapeutic dose.
Primary outcomes:
Secondary outcomes include overdose-related acute care visits or overdose-related death, and treatment discontinuation. The protocol specifies that outcome definitions and ascertainment will rely on linked administrative records available in the provincial databases.
To estimate per-protocol effects, the investigators will implement a target trial framework using cloning, censoring, and weighting (clone-censor-weight). This approach is intended to emulate randomized assignment to sustained titration strategies and to appropriately handle time-varying adherence and censoring due to protocol deviations in observational data. The protocol describes applying these methods to produce comparative effectiveness estimates of alternative titration schedules while addressing confounding and informative censoring inherent in administrative data.
Multiple sensitivity analyses are planned to assess the robustness of findings. These include cohort and timeline restrictions and alternative exposure and outcome definitions. The protocol indicates that these analyses will test whether results are sensitive to how titration schedules, completed induction, and mortality-related outcomes are specified.
Ethics committees (Providence Health Care Research Institute and the Simon Fraser University Office of Research Ethics) waived formal approval because the study uses fully de-identified administrative health data and was classified as a quality improvement initiative; the waiver references Article 2.5 of the Tri-Council Policy Statement. Data access is governed by Data Steward agreements and is not publicly available due to privacy and data-sharing restrictions. The study acknowledges funding from the National Institute on Drug Abuse (R01DA050629). The authors note the report is a preprint and has not undergone peer review.
The protocol frames the anticipated contribution as providing real-world comparative evidence on titration schedules for methadone and buprenorphine/naloxone with respect to completed induction and mortality. The investigators expect that results will inform evidence-based updates to opioid agonist treatment (OAT) guidelines and clinical decision-making in British Columbia and in other jurisdictions confronting escalating opioid-related harms, particularly in contexts with prevalent fentanyl. As this is a protocol and preprint, the authors emphasize that findings will require peer-reviewed publication and consideration by guideline bodies before clinical practice changes.